CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY
Abstract
Background and Aims. Central venous catheters (CVCs) are commonly used in patients with cancer, mainly for the administration of cancer treatments. Catheter-associated upper extremity deep vein thrombosis (UEDVT), also known as catheter-related thrombosis (CRT), is a common complication of CVCs. The available evidence reports rates of symptomatic VTE of 7% over 3 months in patients with active cancer and a new CVC. Current clinical guidelines recommend therapeutic anticoagulation for at least 3 months and as long as the catheter is in place. Evidence on the long-term risk of recurrent venous thromboembolism (VTE) after catheter removal and after treatment discontinuation in patients with ongoing active cancer is scarce, and significant heterogeneity in therapeutic approach after the initial 3-month duration is frequently observed in clinical practice. Our study aims to assess the incidence of recurrent VTE following a first CRT in patients with active cancer who discontinued anticoagulation after completion of at least 3 months of treatment and after line removal. Methods. This is a retrospective multi-center cohort study of adult patients with cancer who have been diagnosed with CRT from Jan 2019 to Dec 2023. Inclusion criteria were discontinuation of anticoagulation, catheter removal, and persistent active cancer. We excluded patients with concomitant other sites VTE, history of VTE, and an indication for long-term anticoagulation (e.g., atrial fibrillation). The minimum duration of follow-up was 90 days after anticoagulant treatment discontinuation. The primary outcome was recurrent VTE. Secondary outcomes included major bleeding events, clinically relevant non-major bleeding events, and all-cause mortality. Assuming a 3% annual rate of recurrent events (corresponding to the observed risk of recurrent events after a first episode of VTE provoked by a transient risk factor in the general population), a calculated sample size of 250 patients would yield an expected one-sided 95% upper confidence bound within 5% (corrected calculation 4.8% evaluated considering normal approximation). Outcomes were calculated as point-estimate risks at 90 days. Kaplan-Meier method was used to estimate the cumulative probability of recurrent VTE, bleeding, and mortality among the overall population. Results. While recruitment is ongoing, we here report the results of the analysis of 117 patients from 5 Italian hospitals. Baseline characteristics and treatment details are described in Table 1. At 90 days after treatment discontinuation, 2 recurrent VTEs (1.7%) occurred. After a median follow-up of 2 years, the cumulative incidence rate was 2.6 (6 events) per 100 patient-years (95% CI 1.2-5.8). Recurrent VTEs were represented by one pulmonary embolism and five UEDVTs, most of them (n:3) related to a new catheter placement and two incidentally diagnosed. No major bleeding events were observed. The mortality rate was 6.9 per 100 patient-years (95% CI 4.2-11.3), and all events were related to the underlying malignancy. Conclusions. Our preliminary results showed that recurrent VTE after anticoagulation discontinuation was relatively low, suggesting that the presence of active cancer alone should not warrant long-term anticoagulation in this setting. Results from a larger sample will be presented at the congress.
Related
- Personalized anticoagulant therapy in venous thromboembolism: current role of direct oral anticoagulants, unmet clinical needs, and future perspectives on Factor XI inhibition
- Risk factors of major bleeding associated with direct oral anticoagulant treatment in patients with venous thromboembolism: a systematic review and meta-analysis
- Anticoagulant Prophylaxis with Edoxaban for Asymptomatic Isolated Distal Deep Vein Thrombosis in Perioperative Hip Fracture Patients.
- Trends in Direct Oral Anticoagulant Use for Cancer-Associated Venous Thromboembolism
- CO015 | EVOLUTION OF ANTICOAGULANT THERAPY FOR CANCER-ASSOCIATED THROMBOSIS: THE START2 REGISTRY ONCO-VTE LONGITUDINAL STUDY
BibTeX
@article{girardi2026co012,
title = {{CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY}},
author = {Laura Girardi},
journal = {Bleeding, Thrombosis and Vascular Biology},
year = {2026},
month = oct,
url = {https://www.btvb.org/btvb/article/view/714},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY
AU - Laura Girardi
PY - 2026
DA - 2026/10/26
JO - Bleeding, Thrombosis and Vascular Biology
UR - https://www.btvb.org/btvb/article/view/714
AB - Background and Aims. Central venous catheters (CVCs) are commonly used in patients with cancer, mainly for the administration of cancer treatments. Catheter-associated upper extremity deep vein thrombosis (UEDVT), also known as catheter-related thrombosis (CRT), is a common complication of CVCs. The available evidence reports rates of symptomatic VTE of 7% over 3 months in patients with active cancer and a new CVC. Current clinical guidelines recommend therapeutic anticoagulation for at least 3 months and as long as the catheter is in place. Evidence on the long-term risk of recurrent venous thromboembolism (VTE) after catheter removal and after treatment discontinuation in patients with ongoing active cancer is scarce, and significant heterogeneity in therapeutic approach after the initial 3-month duration is frequently observed in clinical practice. Our study aims to assess the incidence of recurrent VTE following a first CRT in patients with active cancer who discontinued anticoagulation after completion of at least 3 months of treatment and after line removal. Methods. This is a retrospective multi-center cohort study of adult patients with cancer who have been diagnosed with CRT from Jan 2019 to Dec 2023. Inclusion criteria were discontinuation of anticoagulation, catheter removal, and persistent active cancer. We excluded patients with concomitant other sites VTE, history of VTE, and an indication for long-term anticoagulation (e.g., atrial fibrillation). The minimum duration of follow-up was 90 days after anticoagulant treatment discontinuation. The primary outcome was recurrent VTE. Secondary outcomes included major bleeding events, clinically relevant non-major bleeding events, and all-cause mortality. Assuming a 3% annual rate of recurrent events (corresponding to the observed risk of recurrent events after a first episode of VTE provoked by a transient risk factor in the general population), a calculated sample size of 250 patients would yield an expected one-sided 95% upper confidence bound within 5% (corrected calculation 4.8% evaluated considering normal approximation). Outcomes were calculated as point-estimate risks at 90 days. Kaplan-Meier method was used to estimate the cumulative probability of recurrent VTE, bleeding, and mortality among the overall population. Results. While recruitment is ongoing, we here report the results of the analysis of 117 patients from 5 Italian hospitals. Baseline characteristics and treatment details are described in Table 1. At 90 days after treatment discontinuation, 2 recurrent VTEs (1.7%) occurred. After a median follow-up of 2 years, the cumulative incidence rate was 2.6 (6 events) per 100 patient-years (95% CI 1.2-5.8). Recurrent VTEs were represented by one pulmonary embolism and five UEDVTs, most of them (n:3) related to a new catheter placement and two incidentally diagnosed. No major bleeding events were observed. The mortality rate was 6.9 per 100 patient-years (95% CI 4.2-11.3), and all events were related to the underlying malignancy. Conclusions. Our preliminary results showed that recurrent VTE after anticoagulation discontinuation was relatively low, suggesting that the presence of active cancer alone should not warrant long-term anticoagulation in this setting. Results from a larger sample will be presented at the congress.
SN - 2785-5309
ER -